leukocytes

L-Leucyl-L-Leucine methyl ester hydrochloride (Leu-Leu-ome hydrochloride) 是一种人单核细胞或多形核白细胞产生的 L-亮氨酸甲酯的二肽缩合产物。L-Leucyl-L-Leucine methyl ester hydrochloride 可选择性消除具有细胞毒性潜能的淋巴细胞，也可诱导溶酶体途径应激。

Tulathromycin A (CP 472295) 是一种大环内酯类抗生素，靶向细菌核糖体抑制蛋白质合成 (IC50=0.26 µM)，具有免疫调节作用。它可研究牛和猪的呼吸道疾病。

Aminopterin (4-Aminofolic acid) 是叶酸的 4-氨基衍生物，是叶酸拮抗剂，具有抗癌和免疫抑制活性，用于研究儿童白血病。它催化叶酸还原为四氢叶酸，竞争性抑制二氢叶酸还原酶，Ki 值为 3.7 pM。

MIK665 (S-64315) (S-64315) 对髓系细胞白血病具有抑制作用。

CJ-13,610 是一种具有口服活性的非氧化还原型 5-脂氧合酶 (5-LOX) 抑制剂。 CJ-13,610 抑制白三烯 B4 的生物合成并调节巨噬细胞中 IL-6 mRNA 的表达。

Traxanox 是一种可口服的利尿剂。Traxanox 在体外增强小鼠腹膜巨噬细胞或大鼠腹膜多形核白细胞对酵母颗粒的吞噬作用。Traxanox 对抑制BALB/c小鼠抗体产生的恢复作用。

Traxanox TFA 是一种可口服的利尿剂。Traxanox TFA 在体外增强小鼠腹膜巨噬细胞或大鼠腹膜多形核白细胞对酵母颗粒的吞噬作用。Traxanox TFA 对抑制BALB c小鼠抗体产生的恢复作用。

Nothofagin 具有抗氧化和抗血栓活性，它通过抑制高渗透性、CAMs 的表达以及白细胞的粘附和迁移具有抗炎活性，从而支持其作为血管炎症性疾病的治疗作用。

Methyl retinoate (Retinoic acid, methyl ester) 在体内实验中会诱导给部位发生无菌炎症，会使血液中白细胞数量增加，而红细胞和Hb含量减少。Methyl retinoate 可促进自发性白血病的产生。Methyl retinoate 可用于治疗因维生素A缺乏而产生的胃肥大和溃疡。

Gordonoside J是从菊花茎中分离出的化合物，抑制 LPS 诱导的大鼠多形核白细胞 （PMNS） 中一氧化氮的产生。

(+)-Guaiacin is a compound isolated from the bark of Machilus wangchiana Chun. It shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF).

Alclometasone (7a-Chloro-16a-methyl prednisolone), a glucocorticoid, inhibits leukocytes from releasing pro-inflammatory mediators. It is effective in treating corticosteroid-responsive dermatoses such as atopic dermatitis, psoriasis, allergic dermatitis, and eczema [1].

LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cycloox

1-Stearoyl-sn-glycerol 3-phosphate sodium 作为一种功能性磷脂，主要在膜磷脂的合成过程中由多种细胞类型生成，如活化血小板、上皮细胞、白细胞、神经元和肿瘤细胞。这种化合物在血浆中的常见浓度约为100nM，通过与 G 蛋白偶联受体（GPCR）的相互作用，对细胞的活动、增殖、侵袭、生存及生长因子的产生等多个关键生理过程具有调控作用。其分子结构特征为sn-1位置的硬脂酸和sn-2位置的羟基。

HZ52 是一种有效可逆的5-脂氧合酶(5-LO)抑制剂，在完整的人类多形核白细胞中可阻断白三烯的合成，IC50为 0.7 μM。

LY255283 是白三烯 B4 (LTB4) 受体的特异性拮抗剂，抑制人外周血多形核白细胞和由钙离子载体 A23187 激活的单核细胞中 LTB(4) 的产生。

L 651142 is a weak inhibitor of the platelet-activating factor receptor. It is also binding to polymorphonuclear leukocytes.

Diacetylsplenopentin HCl is used as a synthetic immunomodulator that affects the proliferation and differentiation of bone marrow stem cells without stimulating pathological immune responses beyond the balance of the immune system. This effect is specific

A1777, a selective 5-lipoxygenase inhibitor, reduces leukocytes proliferation without affecting the eosinophils of mast cells.

Gea 3162 is a potent inhibitor of ADP-induced platelet aggregation in platelet rich plasma (PRP). GEA 3162 stimulates cGMP production in granulocytes, platelets, and polymorphonuclear leukocytes.

Traxanox sodium 是一种可口服的利尿剂。Traxanox sodium 在体外增强小鼠腹膜巨噬细胞或大鼠腹膜多形核白细胞对酵母颗粒的吞噬作用。Traxanox sodium 对抑制BALB c小鼠抗体产生的恢复作用。

(±)11(12)-EET is a fully racemic version of the R S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.[1][2][3[]A higher proportion of 11(R),12(S)-EET is produced by the CYP450 isoforms CYP2C23 and CYP2C24 while CYP2B2 produces a higher proportion of 11(S),12(R)-EET.[3]11(12)-EET has been shown, along with 8(9)-EET to play a role in the recovery of depleted calcium pools in cultured smooth muscle cells[4] It also inhibits basolateral 18-pS potassium channels in the renal cortical collecting duct when used at a concentration of 100 nM.[5]11(12)-EET (50 μg kg per day) increases adhesion of isolated peripheral blood leukocytes in a chamber coated with P-selectin and ICAM-1 but does not affect choroidal neovascularization size following laser photocoagulation[6] It also has anti-inflammatory, angiogenic, and cardioprotective properties[7]

PMX-205 is a cyclic hexapeptide that acts as a potent antagonist of C5a receptor (C5aR; IC50= 31 nM).1It is orally active and blocks inflammatory signaling and symptoms in animal models of colitis and allergic asthma.2,3PMX-205 is also brain penetrant and reduces neuroinflammation and neurodegeneration in an animal model of Alzheimer's disease.4 1.March, D.R., Proctor, L.M., Stoermer, M.J., et al.Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activityMol. Pharmacol.65(4)868-879(2004) 2.Jain, U., Woodruff, T.M., and Stadnyk, A.W.The C5a receptor antagonist PMX205 ameliorates experimentally induced colitis associated with increased IL-4 and IL-10Br. J. Pharmacol.168(2)488-501(2013) 3.Staab, E.B., Sanderson, S.D., Wells, S.M., et al.Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthmaInt. Immunopharmacol.21(2)293-300(2014) 4.Fonseca, M.I., Ager, R.R., Chu, S.-H., et al.Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's diseaseJ. Immunol.183(2)1375-1383(2009)

Resolvin E2 (RvE2) is a member of the specialized pro-resolving mediator (SPM) family of bioactive lipids.1It is produced from eicosapentaenoic acidviaan 18-HEPE intermediate, which is formed by aspirin-acetylated COX-2-mediated oxidation of EPA, by 5-lipoxygenase (5-LO) in human polymorphonuclear (PMN) neutrophils.2,3RvE2 (20 ng/animal) inhibits increases in inflammatory exudate neutrophil infiltration in a mouse model of peritonitis induced by zymosan A .3Hepatic RvE2 levels are increased in mice fed normal chow, as well as in a mouse model of high-fat diet-induced non-alcoholic fatty liver disease (NAFLD), by dietary supplementation with EPA.4Plasma levels of RvE2 are increased by dietary supplementation with fish oil containing ω-3 polyunsaturated fatty acids (PUFAs) in patients with peripheral artery disease or chronic kidney disease.1,5,6 1.Chiang, N., and Serhan, C.N.Specialized pro-resolving mediator network: An update on production and actionsEssays Biochem.64(3)443-462(2020) 2.Tjonahen, E., Oh, S.F., Siegelman, J., et al.Resolvin E2: Identification and anti-inflammatory actions: Pivotal role of human 5-lipoxygenase in resolvin E series biosynthesisChemistry & Biology131193-1202(2006) 3.Sungwhan, F.O., Pillai, P.S., Recchiuti, A., et al.Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammationJ. Clin. Invest.121(2)569-581(2011) 4.Echeverría, F., Valenzuela, R., Espinosa, A., et al.Reduction of high-fat diet-induced liver proinflammatory state by eicosapentaenoic acid plus hydroxytyrosol supplementation: Involvement of resolvins RvE1/2 and RvD1/2J. Nutr. Biochem.6335-43(2019) 5.Ramirez, J.L., Gasper, W.J., Khetani, S.A., et al.Fish oil increases specialized pro-resolving lipid mediators in PAD (the OMEGA-PAD II trial)J. Surg. Res.238164-174(2019) 6.Barden, A.E., Shinde, S., Burke, V., et al.The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney diseaseProstaglandins Other Lipid Mediat.1361-8(2018)